Recent Updates
Recently added Catalysts

GW685698

Phase 3

Rhinitis, Allergic, Seasonal | Small molecule | Other |GSK plc|Last Updated: Aug 31, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment65
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00358475Study Of Perennial Allergic RhinitisPHASE3 COMPLETED 65Jun 21, 2005Oct 12, 2005Aug 31, 20181
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Adverse events and laboratory blood test
Secondary Endpoints
Change of nasal symptom score
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Interventions
NameTypeDescription
GW685698DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range16 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion criteria: * Informed consent. * Outpatient. * Diagnosis of perennial allergic rhinitis with symptoms. * Able to comply with study procedures. Exclusion criteria: * Significant concomitant medical condition. * Use of corticosteroids/allergy medications. * Laboratory abnormality. * Positi...

Countries:
Unlock Eligibility Criteria